Newer Potential Pharmacological Targets for Multiple Sclerosis

Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical sciences and research Vol. 12; no. 2; pp. 302 - 304
Main Authors Gejalakshmi, S, Harikrishnan, N
Format Journal Article
LanguageEnglish
Published Cuddalore Journal of Pharmaceutical Sciences and Research 01.02.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS), the most prevalent neurological disability, is an autoimmune-mediated disorder that affects the central nervous system (CNS) and often leads to severe physical or cognitive incapacitation as well as neurological problems in young adult Multifocal zones of inflammation due to focal T-lymphocytic and macrophage infiltrations, and oligodendrocyte death are the primary causes of myelin sheath de- struction that result in the formation of CNS plaques composed of inflammatory cells and their products, demyelinated and transected axons, and astrogliosis in both white and gray matter. Discontinuation of NTZ (usually for safety concerns, due to a high risk of progressive multifocal leukoencephalopathy) is still a dramatic moment in MS therapeutic management and no guidelines exist about the ideal exit strategy. [...]the choice of CD20-depleting agents which reduce the high number of circulating B-cells could be useful. Tight junctions are the critical component of the BCNSB as they control paracellular diffusion and maintain the structural and functional polarity of the specialized endothelial cells of the BBB and BSCB. [...]the BCNSB contributes to the homeostasis of the parenchyma of the brain and spinal cord and provides protection against many toxic compounds and pathogens Indeed, the BCNSB is largely impermeable to compounds that
AbstractList Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS), the most prevalent neurological disability, is an autoimmune-mediated disorder that affects the central nervous system (CNS) and often leads to severe physical or cognitive incapacitation as well as neurological problems in young adult Multifocal zones of inflammation due to focal T-lymphocytic and macrophage infiltrations, and oligodendrocyte death are the primary causes of myelin sheath de- struction that result in the formation of CNS plaques composed of inflammatory cells and their products, demyelinated and transected axons, and astrogliosis in both white and gray matter. Discontinuation of NTZ (usually for safety concerns, due to a high risk of progressive multifocal leukoencephalopathy) is still a dramatic moment in MS therapeutic management and no guidelines exist about the ideal exit strategy. [...]the choice of CD20-depleting agents which reduce the high number of circulating B-cells could be useful. Tight junctions are the critical component of the BCNSB as they control paracellular diffusion and maintain the structural and functional polarity of the specialized endothelial cells of the BBB and BSCB. [...]the BCNSB contributes to the homeostasis of the parenchyma of the brain and spinal cord and provides protection against many toxic compounds and pathogens Indeed, the BCNSB is largely impermeable to compounds that
Author Harikrishnan, N
Gejalakshmi, S
Author_xml – sequence: 1
  givenname: S
  surname: Gejalakshmi
  fullname: Gejalakshmi, S
– sequence: 2
  givenname: N
  surname: Harikrishnan
  fullname: Harikrishnan, N
BookMark eNqNisEKgkAURYcoyMp_GGgtmKNjbtpE0aYQdC-DPG1kmmdvRvr9XPQB3c3hcO6GLS1aWLAgLvIsOqRZsWahc0M8TyRHmYqAnR7wAeIlerBeK8PLp6KXatFgr9vZa0U9eMc7JH6fjNejAV61Bgiddju26pRxEP64ZfvrpT7fopHwPYHzzYAT2Tk1icillJkQsfjv9QU0VDp5
ContentType Journal Article
Copyright Copyright Journal of Pharmaceutical Sciences and Research Feb 2020
Copyright_xml – notice: Copyright Journal of Pharmaceutical Sciences and Research Feb 2020
DBID 04Q
04S
04W
3V.
7X7
7XB
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
PQEST
PQQKQ
PQUKI
PRINS
DatabaseName India Database
India Database: Business
India Database: Science & Technology
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
DatabaseTitle ProQuest Indian Journals
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Indian Journals: Business
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Indian Journals: Science & Technology
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList ProQuest Indian Journals
Database_xml – sequence: 1
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 0975-1459
EndPage 304
GroupedDBID ---
04Q
04S
04W
3V.
7X7
7XB
8AO
8FI
8FJ
8FK
8R4
8R5
ABUWG
ADBBV
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BENPR
BPHCQ
BVXVI
CCPQU
DIK
FRP
FYUFA
HMCUK
K9.
PQEST
PQQKQ
PQUKI
PRINS
PROAC
Q2X
RXW
UKHRP
W2D
ID FETCH-proquest_journals_23766653303
IEDL.DBID 7X7
IngestDate Thu Oct 10 20:11:26 EDT 2024
IsPeerReviewed false
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-proquest_journals_23766653303
PQID 2376665330
PQPubID 54977
ParticipantIDs proquest_journals_2376665330
PublicationCentury 2000
PublicationDate 20200201
PublicationDateYYYYMMDD 2020-02-01
PublicationDate_xml – month: 02
  year: 2020
  text: 20200201
  day: 01
PublicationDecade 2020
PublicationPlace Cuddalore
PublicationPlace_xml – name: Cuddalore
PublicationTitle Journal of pharmaceutical sciences and research
PublicationYear 2020
Publisher Journal of Pharmaceutical Sciences and Research
Publisher_xml – name: Journal of Pharmaceutical Sciences and Research
SSID ssj0000328643
Score 4.290711
Snippet Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly...
SourceID proquest
SourceType Aggregation Database
StartPage 302
SubjectTerms Blood-brain barrier
Immune system
Immunology
Inflammation
Memory
Multiple sclerosis
Nervous system
Pathogenesis
Proteins
Spinal cord
Young adults
Title Newer Potential Pharmacological Targets for Multiple Sclerosis
URI https://www.proquest.com/docview/2376665330
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED90e_FF_MSPOQLKnlZs0yxZXyYqG0NwFK3Qt5EuKfjS6lof9t8vl2VWfNjzwSW5hLvL5Xe_ANxJTWWmWOhJoajHBj7zhipneJa5klxxmlm2zxmffrCXdJC6glvlYJVbn2gdtSoXWCO_R_QG54iFfPj69vDXKHxddV9o7EM7oD5HSJdIxW-NBbniOPbj_HOzNnZMjuDQJX3kcbNLx7CnixPoxRvW6FWfJE0TVNUnPRI3fNKrUxgZR6SXJC5rRPYYPX_EaGKSWDR3RUz-SV4dQJC8m5FMBPyszuB2Mk6ep952dnN3fqp5s9rwHFpFWegLICxi_oKzYIikQZEIs4jmUuQyoBoTJ30JnV2arnaLr-GA4l3SIpI70KqXP_rGBNw661qrdqH9NJ7Fb2v9Oor6
link.rule.ids 315,783,787,12068,21400,31731,33756,43322,43817,74073,74630
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSUw1SkxKMTHWTTRPMdI1MTUw0bVISTMBpWWzlESzFDOjJPBpn35mHqEmXhGmEdABt2LoskpYmQguqFPyk0Fj5Pqg1RtmZqC1kPYFhbqgW6NAs6vQKzSYGVhB53CBbjAwjzCHj7GAzoozA-3HQStmwXWHmyADP7TRp-AIiSUhBqbUPGEGtQDIqdGVOgohiE1QxToKagoBiPOkK0UY7IAFUWqRQkB-CWhlD9AcJGlQECuEgFdzFysA258KvtAFggrBQJuANWBmsSiDsptriLOHLsx18dD0UxyP8K2xGANLXn5eqgSDgomliUGymYmhBejQIEtz4yRLo7RE87REQ6NUUMMpVZJBBp9JUvil5Rk4PUJ8feJ9PP28pRm4jED9SvDqZBkGlpKi0lRZYOVbkiQHDmEAO7uMRw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ3PS8MwFMcfOkG8iD_xx9SAstPKtjRL1osiapm_RsEKvZV0ScFLq2s97L83L8useNg5kCavj_dekk--AbiSmspMMd-TQlGPDfvMG6mcoS9zJbniNLNqnxM-fmdPyTBx_FPlsMplTLSBWpVT3CPvIb3BObKQvdxhEdF9ePP55eELUnjS6p7TWIcNYVYp6PMiEb_7Lagbx_Fuzr-Qa_NIuAPbrgAkt4s_tgtrutiDTrRQkJ53SdxciKq6pEOiRlt6vg_XJijpGYnKGikf08-fZjQ3iS3ZXRFTi5JXBwuSN_Mlkw0_qgO4DB_iu7G3HF3qfKlKm5n7h9AqykIfAWEB6085G4xQQCgQfhbQXIpcDqjGIkofQ3tVTyermy9g0xg3fXmcPJ_CFsUlpgWV29CqZ9_6zOThOju3Bv4B-3uQfw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Newer+Potential+Pharmacological+Targets+for+Multiple+Sclerosis&rft.jtitle=Journal+of+pharmaceutical+sciences+and+research&rft.au=Gejalakshmi%2C+S&rft.au=Harikrishnan%2C+N&rft.date=2020-02-01&rft.pub=Journal+of+Pharmaceutical+Sciences+and+Research&rft.eissn=0975-1459&rft.volume=12&rft.issue=2&rft.spage=302&rft.epage=304&rft.externalDBID=HAS_PDF_LINK